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Introduction
Tumour necrosis factor (TNF) receptor– associated peri-
odic syndrome (TRAPS) is a hereditary autoinflammatory
condition resulting from a range of mutations in the
TNFRSF1A gene. It is characterised in part by recurrent
episodes of inflammation, affecting connective tissues,
and manifesting as migratory erysipelas, myalgia and ser-
ositis. A number of aberrant inflammatory responses
have been described in this condition, including hyperre-
sponsiveness to lipopolysaccharide (LPS). The microRNA
mir155 has been implicated in mediating downstream
pro-inflammatory response to LPS, and it has has also
been implicated in the pathogenesis of rheumatoid
arthritis (RA). Tocilizumab (anti-IL6 receptor antibody)
has been reported to be an effective treatment in at least
one published case of TRAPS.
Objectives
To investigate the effects of LPS challenge on TRAPS
fibroblasts and the roles of IL-6 and mir155 in this
process.
Methods
A patient with a T50M mutation who had previously
failed to respond to etanercept and anakinra was con-
sented to treatment with tocilizumab. Skin fibroblasts
were obtained by biopsy and were propagated ex-vivo.
The effects of LPS, IL-1 and TNF on IL-6 production
were compared between patient’s fibroblasts and fibro-
blasts obtained from a healthy control (HC). TRAPS
and HC fibroblasts, as well as synovial fibroblasts (SFs)
from RA and osteoarthritis (OA) patients were then
subjected to a graded LPS challenge. IL-6 levels were
quantified from media supernatants using ELISA kits
(BD Biosciences). mir155 levels were determined using
qPCR from total RNA.
Results
The patient’s fibroblasts showed greater production of
IL-6 in response to LPS and IL-1 but not TNF when
compared to HC. In the case of RA and OA SFs there
was a dose dependent increase in mir155 levels, whilst, in
the case of TRAPS fibroblasts, the response was not dose
dependent but maximum levels were achieved even at the
minimal dose of LPS (dose range 0.1 ng/l-100ng/l). The
patient had a good clinical response to tocilizumab with a
reduction in the symptoms, decreased steroid use and
resolution of the biochemical markers of inflammation.
Conclusion
Skin fibroblasts are capable of responding to LPS with
production of mir-155 and IL-6. This response appears
to be particularly enhanced in TRAPS fibroblasts, which
may be one of the reasons why a number of clinical man-
ifestations localise to the connective tissue. The ex-vivo
experiments, showing hyperresponsiveness to LPS and
the effective use tocilizumab in this patient would
support a role for IL-6 in the pathogenesis of TRAPS.
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